Anna Shmidt

Mrs. Anna Shmidt


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAnna Shmidt
Anna Shmidt
TETatiana Egorova
Tatiana Egorova
Recombinant adeno-associated viral vectors (rAAV) represent a gene therapy tool of ever-increasing importance. Their utilization as a delivery vehicle for gene replacement, silencing and editing, among other purposes, demonstrate considerable versatility. Emerging vector utilization in various experimental, preclinical and clinical applications establishes the necessity of producing and characterizing a wide variety of rAAV preparations. Critically important characteristics concerning quality control are rAAV titer quantification and the detection of impurities. Differences in rAAV constructs necessitate the development of highly standardized quantification assays to make direct comparisons of different preparations in terms of assembly or purification efficiency, as well as experimental or therapeutic dosages. The development of universal methods for impurities quantification is rather complicated, since variable production platforms are utilized for rAAV assembly. However, general agreements also should be achieved to address this issue. The majority of methods for rAAV quantification and quality control are based on PCR techniques. Despite the progress made, increasing evidence concerning high variability in titration assays indicates poor standardization of the methods undertaken to date. This review summarizes successes in the field of rAAV quality control and emphasizes ongoing challenges in PCR applications for rAAV characterization. General considerations regarding possible solutions are also provided.

1 July 2020 in Experimental Cell Research
Verified
Journal Article
Closed access
KDKirill A. Danilov
Kirill A. Danilov
SVSvetlana . Vassilieva
Svetlana . Vassilieva
APAnna V. Polikarpova
Anna V. Polikarpova
ASAnna V. Starikova
Anna V. Starikova
ASAnna Shmidt
Anna Shmidt
YKYuri Kotelevtsev
Yuri Kotelevtsev

1 April 2022 in Molekulârnaâ biologiâ
Verified
Journal Article
Closed access
ELEvgenii Lunev
Evgenii Lunev
ASAnna Shmidt
Anna Shmidt
SVSvetlana . Vassilieva
Svetlana . Vassilieva
ISIrina M. Savchenko
Irina M. Savchenko
VLVyacheslav A. Loginov
Vyacheslav A. Loginov
MBMaryana V Bardina
Maryana V Bardina
GNAO1 encephalopathy is an orphan genetic disease associated with early infantile epilepsy, impaired motor control, and severe developmental delay. The disorder is caused by mutations in the GNAO1 gene, leading to dysfunction of the encoded protein Gao1. There is no cure for this disease, and symptomatic therapy is ineffective. Phenotypic heterogeneity highlights the need for a personalized approach for treating patients with a specific clinical variant of GNAO1 and requires the study of the disease mechanism in animal and cell models. Towards this aim, we developed an approach for modeling GNAO1 encephalopathy and testing gene therapy drugs in primary neurons derived from healthy mice. We optimized the delivery of transgenes to Gαo1-expressing neurons using recombinant adeno-associated viruses (rAAV). We assessed the tropism of five neurotropic AAV serotypes (1, 2, 6, 9, DJ) for Gαo1-positive neurons from the whole mouse brain. The DJ serotype showed the highest potential as a reporter delivery vehicle, infecting up to 66% of Gαo1-expressing cells without overt cytotoxicity. We demonstrated that AAV-DJ also provides efficient delivery and expression of genetic constructs encoding normal and mutant Gαo1, as well as short hairpin RNA (shRNA) to suppress endogenous Gnao1 in murine neurons. Our results will further simplify the study of the pathological mechanism for clinical variants of GNAO1, as well as optimize the testing of gene therapy approaches for GNAO1 encephalopathy in cell models.

1 January 2023 in Immunologiya
Verified
Journal Article
Open access
MBMaria Byazrova
Maria Byazrova
AMA.A. Mikhailov
A.A. Mikhailov
MSM.M. Sukhova
M.M. Sukhova
MBMaryana V Bardina
Maryana V Bardina
MLMoscow Marlin Biotech Llc
Moscow Marlin Biotech Llc
AFAlexander V Filatov
Alexander V Filatov
Трансдукция В-лимфоцитов человека с помощью аденоассоциированных вирусов различных серотипов